πŸ‡ΊπŸ‡Έ FDA
Patent

US 9662312

Method for treating glomerulosclerosis

granted A61KA61K31/422A61K9/2013

Quick answer

US patent 9662312 (Method for treating glomerulosclerosis) held by Ligand Pharmaceuticals Incorporated expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ligand Pharmaceuticals Incorporated
Grant date
Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/422, A61K9/2013, A61K9/2018, A61K9/2031